Cell-based therapy for therapeutic lymphangiogenesis
- PMID: 25329370
- DOI: 10.1089/scd.2014.0390
Cell-based therapy for therapeutic lymphangiogenesis
Abstract
Lymphedema is a medically irreversible condition for which currently conservative and surgical therapies are either ineffective or impractical. The potential use of progenitor and stem cell-based therapies has offered a paradigm that may provide alternative treatment options for lymphatic disorders. Moreover, basic research, preclinical studies, as well as clinical trials have evaluated the therapeutic potential of various cell therapies in the field of lymphatic regeneration medicine. Among the available cell approaches, mesenchymal stem cells (MSCs) seem to be the most promising candidate mainly due to their abundant sources and easy availability as well as evitable ethical and immunological issues confronted with embryonic stem cells and induced pluripotent stem cells. In this context, the purpose of this review is to summarize various cell-based therapies for lymphedema, along with strengths and weaknesses of these therapies in the clinical application for lymphedema treatment. Particularly, we will highlight the use of MSCs for lymphatic regeneration medicine. In addition, the future perspectives of MSCs in the field of lymphatic regeneration will be discussed.
Similar articles
-
Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.J Vasc Res. 2013;50(2):124-33. doi: 10.1159/000343699. Epub 2012 Nov 27. J Vasc Res. 2013. PMID: 23208012
-
Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo.Circulation. 2009 Jan 20;119(2):281-9. doi: 10.1161/CIRCULATIONAHA.108.793208. Epub 2008 Dec 31. Circulation. 2009. PMID: 19118255
-
Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema.Ann Surg. 2013 May;257(5):961-7. doi: 10.1097/SLA.0b013e31826ed043. Ann Surg. 2013. PMID: 23013803
-
Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation.Trends Immunol. 2004 Jul;25(7):387-95. doi: 10.1016/j.it.2004.05.003. Trends Immunol. 2004. PMID: 15207507 Review. No abstract available.
-
[Primary lymphedema of limbs].Presse Med. 2010 Dec;39(12):1279-86. doi: 10.1016/j.lpm.2010.09.010. Epub 2010 Oct 28. Presse Med. 2010. PMID: 21035299 Review. French.
Cited by
-
A Prospective Study of the Lymphedema and Fibrosis Continuum in Patients with Head and Neck Cancer.Lymphat Res Biol. 2016 Dec;14(4):198-205. doi: 10.1089/lrb.2016.0001. Epub 2016 Jun 15. Lymphat Res Biol. 2016. PMID: 27305456 Free PMC article.
-
Hypoxic conditioned medium from mesenchymal stem cells promotes lymphangiogenesis by regulation of mitochondrial-related proteins.Stem Cell Res Ther. 2016 Mar 11;7:38. doi: 10.1186/s13287-016-0296-1. Stem Cell Res Ther. 2016. PMID: 26968383 Free PMC article.
-
Lymphatic Tissue Bioengineering for the Treatment of Postsurgical Lymphedema.Bioengineering (Basel). 2022 Apr 6;9(4):162. doi: 10.3390/bioengineering9040162. Bioengineering (Basel). 2022. PMID: 35447722 Free PMC article. Review.
-
Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review.Clin Transl Sci. 2021 Jan;14(1):54-61. doi: 10.1111/cts.12864. Epub 2020 Aug 30. Clin Transl Sci. 2021. PMID: 33460321 Free PMC article. Review.
-
Bone Morphogenetic Protein 9 Regulates Early Lymphatic-Specified Endothelial Cell Expansion during Mouse Embryonic Stem Cell Differentiation.Stem Cell Reports. 2019 Jan 8;12(1):98-111. doi: 10.1016/j.stemcr.2018.11.024. Epub 2018 Dec 27. Stem Cell Reports. 2019. PMID: 30595547 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
